Roche Holdings Ltd ADR (RHHBY)

$57.11 -0.59 (-1.02%)
Market Cap 367.58B
Revenue (ttm) 76.45B
Net Income (ttm) 15.54B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 18.12
Profit Margin 20.33%
Debt to Equity Ratio 1.00
Volume 3,509,200
Avg Vol 2,766,894
Day's Range N/A - N/A
Shares Out 6.37B
Stochastic %K 76%
Beta 0.44
Analysts Sell
Price Target $52.72

Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer,...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 41 61 688 88 80
Fax: 41 61 691 00 14
Address:
Grenzacherstrasse 124, Basel, Switzerland
Quantumup
Quantumup Aug. 19 at 11:55 AM
Mizuho⬇️ $LONA's PT to $15 on higher OpEx & stayed Outperform after LONA reported 2Q26 results last Friday (8/14) $AZN $RHHBY NVS LLY PFE - ARVN CELC RLAY SNY BIIB IONS AMLX DNLI BIOA ELDN Mizuho said -- We caught up with management yesterday, and most importantly, LONA's Phase 3 ELAINE-3 study for lead asset lasofoxifene/laso (a selective estrogen receptor modulator/SERM) in treatment-resistant ER+/HER2-ESR1-mutant metastatic breast cancer/BrCa continues to advance, with key milestones (trial enrollment completion in 4Q26, and top-line data in 2H27) still on track. We also discussed progress with the company's ALS asset (ATH-1105, but now called brelgometon) and the company's current finances, but bigger picture, we leave with our positive thesis on LONA intact. On a model update (higher OpEx), we adjust our PT from $16 to $15, but with an implied 95% share upside potential, and in our view, an underappreciated laso market opportunity in breast cancer, we maintain our OP rating on LONA.
0 · Reply
scdtrader213
scdtrader213 Aug. 18 at 3:53 PM
$RHHBY The latest 13F tracking shows 38 institutional buyers versus 25 sellers over the last 12 months. Huge support
0 · Reply
scdtrader213
scdtrader213 Aug. 18 at 3:51 PM
$RHHBY strong chart indicating 60 is next
0 · Reply
DidYouReadThis
DidYouReadThis Aug. 17 at 3:46 PM
$OTLK $RHHBY Is anyone hopeful of a #miscellaneous #surprise? 1. For bevacizumab use in eyes: even if DME and RVO are off label in 2026-unknown, why might an ophthalmologist often choose vs not often choose compounded for: #dme and #rvo as opposed to something still off label for those 2, but with FDA approval for wet AMD indication? 2. How important is safety, efficacy, and affordability to patients, health insurers, and ophthalmologists? 3. Historically, for any injection of compounded bevacizumab for adults, has the volume of bevacizumab been the same regardless of indication? 4. Does anyone know if there’s a general J code for off label indication injections like J3490 or J3590 maybe? 5. Is there possibly any kind of miscellaneous code in Europe for off label use for DME or RVO, or does it vary by country?
0 · Reply
MQuick
MQuick Aug. 17 at 2:13 PM
$GANX its time $SNY $RHHBY $MRK
0 · Reply
HawkEye828
HawkEye828 Aug. 17 at 12:33 PM
$PROK Analysts Sentiment Buy Price Target 6.250 Upside +369.92% https://prokidney.com/clinical-studies/#:~:text=Rilparencel%20is%20being%20developed%20to,the%20patient's%20own%20kidney%20cells. Phase 2 with 70% response rate for kidney disease. Phase 3 on deck. Riprencel cell therapy designed to delay or completely prevent the need for dialysis which is one of the highest Medicare expenses ...at $30 Billion a year/ 90k to 100k per patient. $RHHBY, $NVO, $LLY, $ABBV
1 · Reply
GoforProMIS
GoforProMIS Aug. 14 at 5:26 PM
$PMN new PT from Guggenheim raised to $100 Skipping Phase 2: Question of dosage has been resolved. If a 1b trial as PMN310 tests various escalating dose groups 5 mg to max. dose of 20 mg on actual patients, it has already accomplished the primary objective of Phase 2. Exceptional regarding biomarkers: When evidence is mathematically irrefutable—rendering it logically impossible to question the drugs efficacy— FDA no longer requires an artificial interim study. Impeccable safety at the maximum dose, if the DSMB records a 0.0% incidence of severe side effects at the max. dose during the Phase 1b trial, the primary regulatory hurdle is removed. High unmet medical need: FDA accelerates the process for fatal or incurable diseases like Alzheimer’s. If PMN shows the potential to be safer than existing treatments as Lilly Biogen . FDA views it ethical imperative to expedite the approval process through fast-track programs. $MRK $RHHBY $ABBV
1 · Reply
Top_Dog_Pro_Trader
Top_Dog_Pro_Trader Aug. 14 at 1:30 PM
$SGMO sounds like $LLY back room deal with Sandy might not stand a legal challenge IMO! $REGN $$RHHBY . These assets should have been part of the auction! What a scam/steal by $LLY to try and do this, don’t they have any morals? The sales prices are a tr garage sale prices for assets that can move the needle for even $LLY! One way someone can get around the lawsuit is to buy out the rest of the pipeline. You get the pipeline for some of the future milestone payments, which look very achievable! Come on guys, do you go to church, do you have any ethics? Just offer a decent price!
0 · Reply
genesee273
genesee273 Aug. 14 at 1:05 PM
$OTLK BUYOUT from $RHHBY or $REGN would be Wonderful
0 · Reply
jrh34
jrh34 Aug. 13 at 5:51 PM
$CRDF Perhaps that's already happening - a proxy war with 2 large pharmaceuticals simply using CRDF and NMS as shells to fight over Onvansertib. You'd have $PFE using CRDF and $RHHBY using NMS via the NMS China/Roche Accelerator.
0 · Reply
Latest News on RHHBY
No data available.
Quantumup
Quantumup Aug. 19 at 11:55 AM
Mizuho⬇️ $LONA's PT to $15 on higher OpEx & stayed Outperform after LONA reported 2Q26 results last Friday (8/14) $AZN $RHHBY NVS LLY PFE - ARVN CELC RLAY SNY BIIB IONS AMLX DNLI BIOA ELDN Mizuho said -- We caught up with management yesterday, and most importantly, LONA's Phase 3 ELAINE-3 study for lead asset lasofoxifene/laso (a selective estrogen receptor modulator/SERM) in treatment-resistant ER+/HER2-ESR1-mutant metastatic breast cancer/BrCa continues to advance, with key milestones (trial enrollment completion in 4Q26, and top-line data in 2H27) still on track. We also discussed progress with the company's ALS asset (ATH-1105, but now called brelgometon) and the company's current finances, but bigger picture, we leave with our positive thesis on LONA intact. On a model update (higher OpEx), we adjust our PT from $16 to $15, but with an implied 95% share upside potential, and in our view, an underappreciated laso market opportunity in breast cancer, we maintain our OP rating on LONA.
0 · Reply
scdtrader213
scdtrader213 Aug. 18 at 3:53 PM
$RHHBY The latest 13F tracking shows 38 institutional buyers versus 25 sellers over the last 12 months. Huge support
0 · Reply
scdtrader213
scdtrader213 Aug. 18 at 3:51 PM
$RHHBY strong chart indicating 60 is next
0 · Reply
DidYouReadThis
DidYouReadThis Aug. 17 at 3:46 PM
$OTLK $RHHBY Is anyone hopeful of a #miscellaneous #surprise? 1. For bevacizumab use in eyes: even if DME and RVO are off label in 2026-unknown, why might an ophthalmologist often choose vs not often choose compounded for: #dme and #rvo as opposed to something still off label for those 2, but with FDA approval for wet AMD indication? 2. How important is safety, efficacy, and affordability to patients, health insurers, and ophthalmologists? 3. Historically, for any injection of compounded bevacizumab for adults, has the volume of bevacizumab been the same regardless of indication? 4. Does anyone know if there’s a general J code for off label indication injections like J3490 or J3590 maybe? 5. Is there possibly any kind of miscellaneous code in Europe for off label use for DME or RVO, or does it vary by country?
0 · Reply
MQuick
MQuick Aug. 17 at 2:13 PM
$GANX its time $SNY $RHHBY $MRK
0 · Reply
HawkEye828
HawkEye828 Aug. 17 at 12:33 PM
$PROK Analysts Sentiment Buy Price Target 6.250 Upside +369.92% https://prokidney.com/clinical-studies/#:~:text=Rilparencel%20is%20being%20developed%20to,the%20patient's%20own%20kidney%20cells. Phase 2 with 70% response rate for kidney disease. Phase 3 on deck. Riprencel cell therapy designed to delay or completely prevent the need for dialysis which is one of the highest Medicare expenses ...at $30 Billion a year/ 90k to 100k per patient. $RHHBY, $NVO, $LLY, $ABBV
1 · Reply
GoforProMIS
GoforProMIS Aug. 14 at 5:26 PM
$PMN new PT from Guggenheim raised to $100 Skipping Phase 2: Question of dosage has been resolved. If a 1b trial as PMN310 tests various escalating dose groups 5 mg to max. dose of 20 mg on actual patients, it has already accomplished the primary objective of Phase 2. Exceptional regarding biomarkers: When evidence is mathematically irrefutable—rendering it logically impossible to question the drugs efficacy— FDA no longer requires an artificial interim study. Impeccable safety at the maximum dose, if the DSMB records a 0.0% incidence of severe side effects at the max. dose during the Phase 1b trial, the primary regulatory hurdle is removed. High unmet medical need: FDA accelerates the process for fatal or incurable diseases like Alzheimer’s. If PMN shows the potential to be safer than existing treatments as Lilly Biogen . FDA views it ethical imperative to expedite the approval process through fast-track programs. $MRK $RHHBY $ABBV
1 · Reply
Top_Dog_Pro_Trader
Top_Dog_Pro_Trader Aug. 14 at 1:30 PM
$SGMO sounds like $LLY back room deal with Sandy might not stand a legal challenge IMO! $REGN $$RHHBY . These assets should have been part of the auction! What a scam/steal by $LLY to try and do this, don’t they have any morals? The sales prices are a tr garage sale prices for assets that can move the needle for even $LLY! One way someone can get around the lawsuit is to buy out the rest of the pipeline. You get the pipeline for some of the future milestone payments, which look very achievable! Come on guys, do you go to church, do you have any ethics? Just offer a decent price!
0 · Reply
genesee273
genesee273 Aug. 14 at 1:05 PM
$OTLK BUYOUT from $RHHBY or $REGN would be Wonderful
0 · Reply
jrh34
jrh34 Aug. 13 at 5:51 PM
$CRDF Perhaps that's already happening - a proxy war with 2 large pharmaceuticals simply using CRDF and NMS as shells to fight over Onvansertib. You'd have $PFE using CRDF and $RHHBY using NMS via the NMS China/Roche Accelerator.
0 · Reply
Biotech_Beast
Biotech_Beast Aug. 13 at 5:19 PM
$AUPH doesn't seem to be banking on Lupkynis losing exclusivity any time soon. The phase 4 PRESERVE trial is an opportunity to combine Lupkynis with $RHHBY's Gazyva for Lupus Nephritis, among other combinations. https://seekingalpha.com/article/4935601-aurinia-pharmaceuticals-doubles-down-on-pipeline
0 · Reply
MQuick
MQuick Aug. 13 at 11:25 AM
$GANX its time $SNY $MRK $RHHBY
0 · Reply
Makingmillions192
Makingmillions192 Aug. 10 at 3:14 PM
$LEXX Big Pharma is actively spending billions to secure oral GLP-1 delivery platforms: Novo Nordisk & Vivtex: Signed an up to $2.1B licensing deal to use Vivtex’s oral delivery tech for next-gen obesity pills. Roche & Gasherbrum Bio: Paid $100M upfront to secure non-exclusive patent rights for oral GLP-1 formulation IP. Pfizer & Metsera: Closed a multi-billion-dollar transaction to acquire advanced oral metabolic therapies. These transactions demonstrate that Big Pharma is actively deploying capital into oral delivery technologies. Big Pharma owns the multi-billion-dollar GLP-1 molecules, but specialized small/micro-cap platform companies own the proprietary delivery mechanisms needed to solve stomach degradation, improve bioavailability, and reduce severe GI side effects. Lexaria is next 🔥 $PFE $RHHBY $NVO $LLY
0 · Reply
GoforProMIS
GoforProMIS Aug. 7 at 5:48 PM
$PMN $LLY $BIIB $RHHBY The real jackpot: PMN267 + PMN442 ProMIS describes three key antibody programs: PMN310 → Alzheimer's disease / Amyloid-ß oligomers => PMN310 potential $5-10 bn * PMN267 → ALS / misfolded TDP-43 => PMN267 potential $1-3 bn * PMN442 → Parkinson's disease, MSA, => PMN442 potential $1-3 bn and other synucleinopathies Other Platforms potential $0,5-2 bn means in total range from 7.5-18 bn with a potential Share price of => $405 to $970 This is not pure fantasy.
0 · Reply
GreenEnergy7B
GreenEnergy7B Aug. 7 at 5:05 PM
$ALT GLP1 Glucagon without the best drug for liver disease such as MASH and AUD - as it also results in weight loss, which FGF21 dont . As AUD trial and MASH trial going into phs3, lets see which company see this drug as a strategic fit $GSK $RHHBY $NVO $PFE
0 · Reply
scdtrader213
scdtrader213 Aug. 7 at 3:35 PM
$RHHBY Morgan Stanley upgraded Roche (RHHBY) to overweight from equal-weight, citing several candidates in the Swiss pharma's pipeline that could drive growth. The investment bank raised its price target to $63 from $46
0 · Reply
Diefreeandsell
Diefreeandsell Aug. 7 at 12:44 PM
$REPL So expect an offering soon, followed up by roadshow followed up by $BMY Bo after co secures cash from offering. Prob $GS already working on just such a scenario. Maybe a bidding war erupts w $REGN or $RHHBY
1 · Reply
Quantumup
Quantumup Aug. 7 at 10:42 AM
Raymond James⬆️ $TRVI's PT to $40 from $27 and keeps at a Strong Buy after adding the non-IPF ILD indication to its model (70% PoS, $1.16B peak unadj'd sales in '35—⬆️its assumption for WAC pricing of Haduvio. $RHHBY VRNA - $MRK 𝑮̶𝑺̶𝑲̶ Here's what Raymond James said in its note to investors: https://x.com/Quantumup1/status/2085677838485606488?s=20
0 · Reply
IncelBull
IncelBull Aug. 6 at 1:59 PM
$LULU the LGBTQ community and women will need to downsize their yogapants after using pharmaceutical grade GLP-1s from companies such as $AZN $SNY $RHHBY $VKTX
1 · Reply
Makingmillions192
Makingmillions192 Aug. 6 at 10:04 AM
$LEXX Recent macro trends in the GLP-1 sector directly strengthen Lexaria’s strategic position: Medicare Coverage Expansion: CMS expanded its $50/month copay bridge program, driving retail channels to push lower-cost options. Capped reimbursements force Big Pharma to seek high-margin, scalable oral pills over expensive cold-chain injectables. Focus on Tolerability: Rapid oral market growth has shifted competition to patient adherence. DehydraTECH’s core value—reducing GI side effects and accelerating absorption—solves the primary cause of therapy discontinuation. (Inline with commentary following BIO convention) Persistent Supply Bottlenecks: Injectable autoinjector shortages remain a barrier, accelerating Big Pharma’s urgency to license proven oral drug-delivery platforms. There are so many companies that want in on this sector that could fast track years of R&D by buying or licensing Lexaria’s DHT tech. $LLY $NVO $RHHBY $VKTX
0 · Reply
scdtrader213
scdtrader213 Aug. 3 at 1:28 PM
$RHHBY slow and steady towards $60.00
0 · Reply
drdr3
drdr3 Aug. 2 at 2:12 AM
$MCRB $PFE RHHBY $RHHBY
0 · Reply